All News

In the RE104 group receiving the 30-mg dose, clinically meaningful reductions in the primary endpoint were seen on day 1 posttreatment and sustained through day 28 follow-up.

AstraZeneca launches FluMist Home, the first FDA-approved at-home flu vaccine service, allowing self- or caregiver administration of the intranasal influenza vaccine for the 2025–26 season.

If FIT results indicated colonoscopy, respondents preferred personal follow-up vs digital; significant barriers to undergoing fear of the test and positive cancer finding were the most significant barriers to follow-up.

Your daily dose of the clinical news you may have missed.

The accelerated approval for semaglutide 2.4 mg for the treatment of noncirrhotic MASH was based on part 1 of the phase 3 ESSENCE trial, which met its primary endpoints.

The US FDA approved Tonmya, a groundbreaking treatment for fibromyalgia, offering hope to millions experiencing chronic pain and sleep issues.

Updates to the 2017 guideline focus on new monitoring strategies, earlier intervention to reduce cognitive decline, improved perinatal care, and refined risk assessment.

Explore the latest insights on diabetes in pregnancy, asthma management disparities, AI in health care, dementia risk reduction, and new eczema treatments.

Please remind your adult patients that these recommended vaccines (eg, pneumococcal, flu, HPV) are essential to protect them, and their communities, from serious outcomes.

Your daily dose of the clinical news you may have missed.

Infectious disease expert Amesh Adalja, MD, discusses key vaccine policy changes, strategies to combat misinformation, and ways PCPs can boost vaccine confidence.

A recent poll reveals most US adults are hesitant about fall COVID-19 vaccinations, highlighting confusion over federal policies and declining trust in health agencies.

William Schaffner, MD, a veteran infectious disease expert and public health thought leader is concerned that rapidly shifting federal policy could impact future options.

Fewer than 1 in 5 eligible older adults in the US received the RSV vaccine during the first 2 seasons it was available, and uptake was lower based on SDOH.

The US FDA approved brensocatib as the first treatment for non–cystic fibrosis bronchiectasis.

RDX-002, an investigational, first-in-class therapeutic, significantly reduced weight regain after cessation of antiobesity treatment with semaglutide and tirzepatide.

The 9 influenza vaccines available for the upcoming respiratory virus season come from 4 manufacturers in single-dose syringes and vials and multidose vials may still be available.

Family physician Sarah Sams, MD, shares how to improve pediatric vaccine coadministration using pre‑visit planning and staff coordination.